Regencell Bioscience Holdings Limited (RGC) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Causeway Bay, 홍콩. 현재 CEO는 Yat-Gai Au.
RGC 을(를) 보유 IPO 날짜 2021-07-16, 12 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $14.89B.
Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company incorporated in 2014 and headquartered in Causeway Bay, Hong Kong. The company specializes in the research, development, and commercialization of TCM-based treatments for neurocognitive disorders and degeneration, with a primary focus on attention deficit hyperactivity disorder and autism spectrum disorder. Through its integrated approach to traditional medicine and modern science, Regencell aims to address significant unmet medical needs in neurological health.
